TrialPloS one2013

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

Yasmin Issa-Nummer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.